The stock of Theratechnologies Inc. (THTX) has seen a -2.44% decrease in the past week, with a -13.04% drop in the past month, and a -9.09% decrease in the past quarter. The volatility ratio for the week is 7.80%, and the volatility levels for the past 30 days are at 4.81% for THTX. The simple moving average for the past 20 days is -6.56% for THTX’s stock, with a -17.41% simple moving average for the past 200 days.
Is It Worth Investing in Theratechnologies Inc. (NASDAQ: THTX) Right Now?
Company’s 36-month beta value is 1.40.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for THTX is 19.11M, and currently, short sellers hold a 0.07% ratio of that floaft. The average trading volume of THTX on September 19, 2024 was 38.28K shares.
THTX) stock’s latest price update
Theratechnologies Inc. (NASDAQ: THTX) has experienced a decline in its stock price by -12.41 compared to its previous closing price of 1.37. However, the company has seen a fall of -2.44% in its stock price over the last five trading days. globenewswire.com reported 2024-09-17 that MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV ® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.
Analysts’ Opinion of THTX
Many brokerage firms have already submitted their reports for THTX stocks, with Cantor Fitzgerald repeating the rating for THTX by listing it as a “Overweight.” The predicted price for THTX in the upcoming period, according to Cantor Fitzgerald is $9 based on the research report published on November 17, 2022 of the previous year 2022.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see THTX reach a price target of $3, previously predicting the price at $8. The rating they have provided for THTX stocks is “Hold” according to the report published on July 29th, 2021.
THTX Trading at -12.73% from the 50-Day Moving Average
After a stumble in the market that brought THTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.49% of loss for the given period.
Volatility was left at 4.81%, however, over the last 30 days, the volatility rate increased by 7.80%, as shares sank -13.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.58% lower at present.
During the last 5 trading sessions, THTX fell by -2.44%, which changed the moving average for the period of 200-days by -24.05% in comparison to the 20-day moving average, which settled at $1.2750. In addition, Theratechnologies Inc. saw -25.93% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for THTX
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.75 for the gross margin
The net margin for Theratechnologies Inc. stands at -0.08. The total capital return value is set at 0.27.
Based on Theratechnologies Inc. (THTX), the company’s capital structure generated 1.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at -2.54. The interest coverage ratio of the stock is 0.44.
Currently, EBITDA for the company is -7.54 million with net debt to EBITDA at 3.79. When we switch over and look at the enterprise to sales, we see a ratio of 1.01. The receivables turnover for the company is 6.08for trailing twelve months and the total asset turnover is 1.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.10.
Conclusion
In a nutshell, Theratechnologies Inc. (THTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
